Literature DB >> 11051246

Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins.

R N Clayton1, M Pfeifer, A B Atkinson, P Belchetz, J A Wass, E Kyrodimou, M Vanderpump, D Simpson, J Bicknell, W E Farrell.   

Abstract

Sporadic human pituitary tumors are benign adenomas of monoclonal origin. This implies that they arise from de novo somatic mutation(s) within a single pituitary cell. The availability of original and recurrent/regrown tumors from the same patient allowed testing of the prediction that recurrent/regrown tumors have identical genetic abnormalities as the original tumor sample. We used PCR amplification, from archival slide-extracted DNA, to allelotype microsatellite polymorphisms as an indication of clonality and confirmed this by X chromosome inactivation analysis in samples from women. Tumors from 33 of 49 (67%) patients with two or more specimens showed loss of heterozygosity (LOH) of at least one marker in at least one of their samples. Two patterns of LOH were observed. In pattern A in 14 of 33 (42%) of patients, the LOH pattern of the first tumor was preserved in the second recurrent sample, with some recurrent tumors also showing additional LOH. In these patients, the original and second tumors are presumed to arise from the same original clone with or without progressive accumulation of LOH. In pattern B [19 of 33 (58%) patients], LOH seen in the first tumor was not preserved in the second or subsequent tumors, as evidenced by retention of heterozygosity compared with the first tumor. The simplest explanation is that the second tumor, although still monoclonal, arises from another independently abnormal clone. This was confirmed by X chromosome inactivation analysis in all 11 women where this was informative. These results show that initial and recurrent tumors, of a benign tumor type, are frequently derived from separate independent clones. This suggests that either: (a) more than one abnormal clone is present from the outset though only one dominates; or (b) several clones arise independently at different times. In both scenarios, the initiating event(s) that predisposes to transformation might result in multiclonal hyperplasia, possibly as a consequence of exogenous stimulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11051246

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

1.  Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas.

Authors:  M Filopanti; E Ballarè; A G Lania; S Bondioni; U Verga; M Locatelli; L M Zavanone; M Losa; S Gelmini; A Peri; C Orlando; P Beck-Peccoz; A Spada
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

Review 2.  Epidemiology and etiopathogenesis of pituitary adenomas.

Authors:  Elena D Aflorei; Márta Korbonits
Journal:  J Neurooncol       Date:  2014-01-31       Impact factor: 4.130

3.  Pituitary carcinoma with endolymphatic sac metastasis.

Authors:  Irida Balili; Steven Sullivan; Paul Mckeever; Ariel Barkan
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

4.  Identification of a novel RASD1 somatic mutation in a USP8-mutated corticotroph adenoma.

Authors:  Andrew V Uzilov; Khadeen C Cheesman; Marc Y Fink; Leah C Newman; Chetanya Pandya; Yelena Lalazar; Marco Hefti; Mary Fowkes; Gintaras Deikus; Chun Yee Lau; Aye S Moe; Yayoi Kinoshita; Yumi Kasai; Micol Zweig; Arpeta Gupta; Daniela Starcevic; Milind Mahajan; Eric E Schadt; Kalmon D Post; Michael J Donovan; Robert Sebra; Rong Chen; Eliza B Geer
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-05

Review 5.  Architects of Pituitary Tumour Growth.

Authors:  Maria Eugenia Sabatino; Ezequiel Grondona; Ana Lucía De Paul
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-28       Impact factor: 6.055

6.  Potential contribution of SIM2 and ETS2 functional polymorphisms in Down syndrome associated malignancies.

Authors:  Arpita Chatterjee; Samikshan Dutta; Sanjit Mukherjee; Nupur Mukherjee; Avirup Dutta; Ashis Mukherjee; Swagata Sinha; Chinmay Kumar Panda; Keya Chaudhuri; Ananda L Roy; Kanchan Mukhopadhyay
Journal:  BMC Med Genet       Date:  2013-01-23       Impact factor: 2.103

7.  Somatotropes maintain their immature cells through Insulin-like growth factor I (IGF-I).

Authors:  Kotaro Yokoyama; Chihiro Mogi; Kaoru Miura; Keisuke Kuroda; Kinji Inoue
Journal:  Endocr Pathol       Date:  2007       Impact factor: 4.056

Review 8.  Stem/progenitor cells in pituitary organ homeostasis and tumourigenesis.

Authors:  Scott Haston; Saba Manshaei; Juan Pedro Martinez-Barbera
Journal:  J Endocrinol       Date:  2017-08-30       Impact factor: 4.286

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.